user

Practical use of osimertinib in Japanese patients with EGFR T790M mutation positive advanced non-small-cell lung cancer

被引：0
|
作者：
Kotake, M. [1 ]
Murakami, H. [1 ]
Naito, T. [1 ]
Takahashi, T. [1 ]
Kenmotsu, H. [1 ]
Ono, A. [1 ]
Wakuda, K. [1 ]
Nakashima, K. [1 ]
Omori, S. [1 ]
机构：
[1] Shizuoka Canc Ctr, Thorac Oncol, Shizuoka, Japan
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
456P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial
    Akamatsu, Hiroaki
    Katakami, Nobuyuki
    Okamoto, Isamu
    Kato, Terufumi
    Kim, Young Hak
    Imamura, Fumio
    Shinkai, Masaharu
    Hodge, Rachel A.
    Uchida, Hirohiko
    Hida, Toyoaki
    CANCER SCIENCE, 2018, 109 (06): : 1930 - 1938
  • [2] The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer
    Gao, Xin
    Le, Xiuning
    Costa, Daniel B.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (04) : 383 - 390
  • [3] Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status
    Nakashima, Kazuhisa
    Kimura, Madoka
    Akamatsu, Hiroaki
    Daga, Haruko
    Imai, Hisao
    Taira, Tetsuhiko
    Ko, Ryo
    Hisamatsu, Yasushi
    Nishino, Kazumi
    Sugimoto, Takeya
    Miyashita, Yosuke
    Takahashi, Toshiaki
    Kumagai, Toru
    Yamamoto, Nobuyuki
    Murakami, Haruyasu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (07) : 671 - 675
  • [4] Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
    Soejima, Kenzo
    Yasuda, Hiroyuki
    Hirano, Toshiyuki
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (01) : 31 - 38
  • [5] Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutation
    Imamura, Fumio
    Kimura, Madoka
    Yano, Yukihiro
    Mori, Masahide
    Suzuki, Hidekazu
    Hirashima, Tomonori
    Ihara, Shouichi
    Komuta, Kiyoshi
    Shiroyama, Takayuki
    Nagatomo, Izumi
    Kumagai, Toru
    FUTURE ONCOLOGY, 2020, 16 (21) : 1537 - 1546
  • [6] Targeting the EGFR T790M mutation in non-small-cell lung cancer
    Normanno, Nicola
    Maiello, Monica Rosaria
    Chicchinelli, Nicoletta
    Iannaccone, Alessia
    Esposito, Claudia
    De Cecio, Rossella
    D'alessio, Amelia
    De Luca, Antonella
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2017, 21 (02) : 159 - 165
  • [7] Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer who have poor performance status
    Kimura, Madoka
    Nishino, Kazumi
    Imamura, Fumio
    Nakashima, Kazuhisa
    Takahashi, Toshiaki
    Sugimoto, Takeya
    Akamatsu, Hiroaki
    Yamamoto, Nobuyuki
    Daga, Haruko
    Imai, Hisao
    Taira, Tetsuhiko
    Miyashita, Yosuke
    Ko, Ryo
    Hisamatsu, Yasushi
    Murakami, Haruyasu
    ANNALS OF ONCOLOGY, 2018, 29
  • [8] Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
    Khozin, Sean
    Weinstock, Chana
    Blumenthal, Gideon M.
    Cheng, Joyce
    He, Kun
    Zhuang, Luning
    Zhao, Hong
    Charlab, Rosane
    Fan, Ingrid
    Keegan, Patricia
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2017, 23 (09) : 2131 - 2135
  • [9] Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
    Skoulidis, Ferdinandos
    Papadimitrakopoulou, Vassiliki A.
    CLINICAL CANCER RESEARCH, 2017, 23 (03) : 618 - 622
  • [10] Therapeutic approaches for T790M mutation positive non-small-cell lung cancer
    Attili, Ilaria
    Karachaliou, Niki
    Conte, PierFranco
    Bonanno, Laura
    Rosell, Rafael
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (10) : 1021 - 1030
12345